ICH Q3D(R2): Limits for Elemental Impurities by the Cutaneous and Transcutaneous Route and Some Corrected Permitted Daily Exposures (PDEs) (Step 2)

Step 2 document – to be released for comments

28 09, 2020

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Legal Notice

• This presentation is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.

• The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.

• The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.
Background

• The documents has been signed off as a Step 2 documents (25th Sep. 2020) to be issued by the ICH Regulatory Members for public consultation

• These documents were developed based on a Concept Paper (15th Sep. 2016) and an updated Work Plan (30th June 2020)

• Anticipating finalization as a Step 4 document to be implemented in the local regional regulatory system: July / 2021
ICH Q3D(R2): Cutaneous PDEs and error corrections

Key Principles

• This presentation will provide a summary of the proposed new appendix for “Limits for Elemental Impurities by the Cutaneous and Transcutaneous Route”

• This presentation will concomitantly provide summaries of the proposed error corrections to the PDEs of 3 elemental impurities in ICH Q3D(R1).
Guideline Objectives

• The objectives and scope remain the same as indicated in the ICH Q3D Guideline finalized in December 2014.

• The Guideline revision (R2) is focused on establishment of limits for elemental impurities by the dermal route of exposure.

• The Guideline revision (R2) also includes error corrections of the PDEs for silver (oral), gold (oral, parenteral and inhalation) and Nickel (inhalation).
Table of Contents

• Summary of limits for elemental impurities (EI) by the cutaneous and transcutaneous route

• Error correction of silver(Ag) PDE by oral route exposure

• Error corrections of the gold(Au) PDEs by oral, parenteral and inhalation routes exposure

• Error correction of nickel(Ni) by inhalation route exposure
Summary of cutaneous PDEs

- The new appendix document of cutaneous PDEs of elemental impurities were developed by the EWG. The table of contents of the appendix is as follows.

1. Background
2. Scope
3. Principles of Safety Assessment for Cutaneous Products
4. Establishing The Cutaneous Permitted Daily Exposure (PDE)
5. Cutaneous Concentration Limits for Ni And Co
6. Product Risk Assessment
7. Cutaneous PDE Values
8. References
Summary of cutaneous PDEs (1)

- **Background**
  - Dermal absorption is dependent upon the properties of the skin, the anatomical site, the nature of the chemical applied and the characteristics of the application. But quantitative data are generally lacking for most EI and its ions.
  - A generic approach was adopted to establish limits as opposed to an element-by-element basis.

- **Scope**
  - This Appendix does not apply to drug products intended for mucosal administration, topical ophthalmic, rectal, or subcutaneous and subdermal routes of administration.
Summary of cutaneous PDEs (2)

• Principles of Safety Assessment
  - In general, there is no indication for local toxicity on the skin, with the exception of sensitization.
  - A generic approach for deriving a cutaneous PDE has been developed based on a systematic adjustment of the parenteral PDE, which assumes 100% bioavailability.
  - The available data indicate that EIs are generally poorly absorbed through intact skin even in the presence of enhancers.
  - For drug products intended to treat skin with substantial disruption of the basal cell layer of the epidermis, the parenteral PDE is generally an appropriate starting point.
Summary of cutaneous PDEs (3)

• Establishing The Cutaneous PDE (for systemic toxicity)

- The limited available data suggest that transcutaneous absorption of most EI is less than 1% for intact skin
- The Cutaneous Modifying Factor (CMF) was developed for deriving protective PDE due to lack of reliable quantitative data

1. For EIs other than arsenic (As) and thallium (Tl), a maximum Cutaneous Bioavailability (CBA) of 1% is used.
2. To account for the various factors that can enhance CBA, a factor of 10 is applied to increase the CBA (adjusted CBA).
3. To calculate the CMF, the parenteral BA (100%) is divided by the adjusted CBA
ICH Q3D(R2): Cutaneous PDEs and error corrections

Summary of cutaneous PDEs (4)

• Establishing The Cutaneous PDE (for systemic toxicity)

Cutaneous PDE = Parenteral PDE x CMF

➢ PDE for EIs (other than TI and As) (CMF=10)
  (Adjusted CBA = 1%(absorption) X10 =10%; ∴CMF = 100% / 10% = 10)
  ● Cutaneous PDE = Parenteral PDE x 10

➢ PDE for As (CMF = 2, absorption is approximately 5%)
  (Adjusted CBA = 5%(absorption) X10 =50%; ∴CMF = 100% / 50% = 2)
  ● Cutaneous PDE = 15 μg/day x 2 = 30 μg/day

➢ PDE for TI (CMF = 1, absorption is high, but no quantitative data)
  (Adjusted CBA = 100% (absorption); ∴CMF = 100% / 100% = 1)
  ● Cutaneous PDE = 8 μg/day x 1 = 8 μg/day
Summary of cutaneous PDEs (5)

• Cutaneous and Transcutaneous Concentration Limits (CTCL) for Ni and Co

- The CTCL in addition to the PDE is warranted for Ni and Co to reduce the likelihood of eliciting skin reactions in already sensitized individuals.

- The dermal concentration limit of 0.5 μg/cm²/week (EU directive) is applied to set a CTCL of Ni
  - Application of 0.5 g dose to a skin surface area of 250 cm²

\[
0.5 \, \text{μg/cm}^2/\text{week} = 0.07 \, \text{μg/cm}^2/\text{day} \\
0.07 \, \text{μg/cm}^2/\text{day} \times 250 \, \text{cm}^2 = 17.5 \, \text{μg/day} \\
17.5\, \text{μg/day}/0.5 \, \text{g} = 35 \, \text{μg/g}
\]

- Recent report suggested Co shows a similar limit to Ni
Summary of cutaneous PDEs (6)

Product Risk Assessment

- Product assessments for cutaneous drug products should be prepared following the guidance provided in Q3D Section 5.
- For Ni and Co, the concentration (µg/g) in the drug product should be assessed relative to the CTCL, in addition to the PDE.
- The total Ni and Co level (µg/day) is at or below the PDE, and their respective concentrations do not exceed the CTCL.
- “Control threshold” approach is also applied to the CTCL.
- Evaluation of the retention during typical conditions of use is important. (see Module 1, ICH Q3D training package)
Error correction of Ag PDE by parenteral route

• The parenteral PDE for silver (Ag) is based on a lowest observed adverse effect level (LOAEL) of 0.014 mg/kg using long-term human intravenous exposure data. But, the cited LOAEL (from the reference dose (RfD) of USEPA IRIS document) in the monograph had been already adjusted for oral route exposure.

• After further review, the original study cited in the monograph was considered in error. It was considered inadequate to set a parenteral PDE as it involved a low number of patients and the dosing was not adequately described.
Error correction of Ag PDE by parenteral route

• The EWG developed the corrected parenteral PDE as follows

• In a review of the oral toxicity of silver, Hadrup and Lam (2014) report that absorption of a radionuclide of silver (as silver nitrate) was 18% in human.

• the parenteral PDE was calculated by dividing the oral PDE by a modifying factor of 10 (as described in Section 3.1). (in the case of oral bioavailability between 1% and 50%)

• The recommended PDE for silver for parenteral exposure is:

  \[ \text{PDE} = \frac{167 \ \mu g/day}{10} = 16.7 \ \mu g/day \]

• The rounded parenteral PDE in Table A.2.1 is 15 \( \mu g/day \)
Error correction of Au PDE by all route

- The monograph of Gold(Au) explained that “derivation of the oral PDE of Au is based on a study in mice (Ahmed 2012)” But, the study was conducted in rats.
- F1 of 5 (for rats) in PDE calculation should be used instead of F1 of 12 (for mice)
- The oral PDE calculation should be corrected as follows.
  \[
  \text{PDE} = \frac{32.2 \text{ mg/kg} \times 50 \text{ kg}}{12} \times 10 \times 10 \times 1 \times 10 = 134 \mu\text{g/day}
  \]
  \[
  \text{PDE} = \frac{32.2 \text{ mg/kg} \times 50 \text{ kg}}{5} \times 10 \times 10 \times 1 \times 10 = 322 \mu\text{g/day}
  \]
  The parenteral PDE is same as the oral PDE, and the inhalation PDE is 1/100 of the oral PDE
- The PDEs in Table A.2 should be also corrected as follows.

<table>
<thead>
<tr>
<th>Monograph</th>
<th>Oral</th>
<th>parenteral</th>
<th>inhalation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Au</td>
<td>322</td>
<td>322</td>
<td>3.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table A.2.1</th>
<th>oral</th>
<th>parenteral</th>
<th>inhalation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Au</td>
<td>300</td>
<td>300</td>
<td>3</td>
</tr>
</tbody>
</table>
Error correction of Ni PDE by inhalation route

• The derivation procedure of Ni PDE by inhalation in the Q3D Step 4 document in 2014 was not changed from that in the Q3D Step 2 document in 2013. There was no issue or discussion between the Q3D Step 2 and Q3D Step 4.

• The EWG concluded that the current PDE of Ni by inhalation was a transcription error at the Q3D Step 4 publication in 2014.

• The EWG recommend that the PDE of Ni by inhalation in Table A.2.1 should be corrected to “6 μg/day” from “5 μg/day” (There is no need to change the Ni monograph itself).
Conclusions (1)

• Develop a new appendix for “Limits for Elemental Impurities by the Cutaneous and Transcutaneous Route”

• This appendix does not apply to drug products intended for mucosal administration, topical ophthalmic, rectal, or subcutaneous and subdermal routes of administration

• Establish the cutaneous PDE of all EIs for systemic toxicity (See Table 1 of the appendix)

• Establish the CTCL for Ni and Co for sensitized patients

• The total Ni or Co level is at or below the cutaneous PDE, and their respective concentrations do not exceed the CTCL
Conclusions (2)

• The original PDEs for silver (Ag), for gold (Au), and for nickel (Ni) were incorrect due to calculation or transcription errors.

• The EWG re-evaluated the relevant data and identified the corrected PDE of Ag, and corrected a modifying factor of Au, and corrected a transcription error of Ni.

• The corrected PDE of Ag by the parenteral route is identified as 15 µg/day.

• The corrected PDE of Au by the oral, parenteral or inhalation routes is identified as 300, 300, 3 µg/day, respectively.

• The corrected PDE in Table A2.1 of Ni by the inhalation route is identified as 6 µg/day.
Contact

• For any questions please contact the ICH Secretariat:

admin@ich.org